A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control

Many patients with diabetes mellitus (both type 1 and type 2) require therapy to maintain normal fasting glucose levels. To develop a novel treatment for these individuals, we used phage display technology to target the insulin receptor (INSR) complexed with insulin and identified a high affinity, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhaskar, Vinay, Goldfine, Ira D., Bedinger, Daniel H., Lau, Angela, Kuan, Hua F., Gross, Lisa M., Handa, Masahisa, Maddux, Betty A., Watson, Susan R., Zhu, Shirley, Narasimha, Ajay J., Levy, Raphael, Webster, Lynn, Wijesuriya, Sujeewa D., Liu, Naichi, Wu, Xiaorong, Chemla-Vogel, David, Tran, Catarina, Lee, Steve R., Wong, Steve, Wilcock, Diane, White, Mark L., Corbin, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3331746/
https://www.ncbi.nlm.nih.gov/pubmed/22403294
http://dx.doi.org/10.2337/db11-1578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3331746/
https://www.ncbi.nlm.nih.gov/pubmed/22403294
http://dx.doi.org/10.2337/db11-1578

Ejemplares similares